MPNs

A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.

Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.

Based on a systematic review and meta-analysis , investigators say allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosi.

The FDA has accepted and granted priority review to a new drug application for pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L.

After receiving a complete response letter by the FDA, an approval application for ropeginterferon alfa-2b for treatment for patients with polycythemia vera. has been resubmitted to the FDA.

In an interview with Targeted Oncology, Naseema Gangat, MD, MBBS, discussed her recommendations for managing pregnant patients with myeloproliferative neoplasms.

Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.

The most recent data on ruxolitinib support its continued use as frontline treatment of patients with myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the impacts of an analysis demonstrating longer survival in patients with myelofibrosis who received ruxolitinib versus those who didn’t.

A phase 3 study with the goal of demonstrating overall survival benefit with imetelstat versus best available therapy in patients with refractory myelofibrosis has dosed the first patient with the experimental agent.

The addition of parsaclisib to ruxolitinib led to improvement in spleen volume reduction and symptom burden in patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone, according to results from a phase 2 study.

A rolling submission of a New Drug Application has been completed for pacritinib which is seeking FDA approval as a treatment for patients with myelofibrosis who have severe thrombocytopenia.

In patients with polycythemia vera, long-term use of the histone deacetylase inhibitor givinostat may be warranted after the agent demonstrated tolerable safety and good efficacy over a 4-year period in an ongoing, multicenter, open-label, single-arm study of patients with a chronic myeloproliferative neoplasm who are positive for a JAK2 V617F mutation.

Naveen Pemmaraju, MD, discusses the results of combining ruxolitinib and navitoclax in different high-risk populations of relapsed/refractory myelofibrosis.

Major thrombosis is a significant danger for patients with MPN who become infected with COVID-19, and antithrombotic prophylaxis does not appear to eliminate the risk.

The FDA has issued a complete response letter to PharmaEssentia Corporation for the company’s biologics license application for ropeginterferon alfa-2b-njft as a potential treatment for patients with polycythemia vera.

Lucia Masarova, MD, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST trial in patients with myelofibrosis.

Ruxolitinib is one of only 2 treatments for MF that significantly improved the survival of patients. Still oncologists see opportunity to prolong survival in these patients even more.

Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.

Data from a prospective pilot trial presented at the 2021 Transplantation and Cellular Therapy Meetings show that a maximum dose of 10 mg of ruxolitinib given peri-transplant is a safe and feasible treatment for patients with myelofibrosis.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, reviewed the prognostic tools used to find indicators of response to treatment in patients with myelofibrosis, during a Targeted Oncology Case-Based Peer Perspective Roundtable discussion.

A new meta-analysis confirms that ASXL1 mutations could be an important prognostic indicator in patients with myeloproliferative neoplasms.

JAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.

In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed the potential role of an add-back strategy as treatment of patients with myelofibrosis who no longer benefited from prior ruxolitinib.

Twenty-four or more cycles of fedratinib was well-tolerated in patients with intermediate- or high-risk myelofibrosis treated in either the phase 1/2 TED12015 study or the phase 1 TED12037 study. The long-term safety and tolerability results of fedratinib.